Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

NCT: NCT04065490 · COMPLETED

NCT IDNCT04065490
StatusCOMPLETED
Start Date2019-09-23
Completion2024-11-01
SponsorLumiThera, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. Alcon Research, LLC, acquired LumiThera in September 2025.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑